Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer

被引:31
|
作者
de Geus-Oei, LF [1 ]
Oei, HY [1 ]
Hennemann, G [1 ]
Krenning, EP [1 ]
机构
[1] Univ Rotterdam Hosp, Dept Nucl Med, Dijkzigt, Netherlands
关键词
differentiated thyroid carcinoma; follow-up; iodine-123; iodine-131; thyroglobulin;
D O I
10.1007/s00259-002-0781-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Primary treatment of differentiated thyroid carcinoma consists of total thyroidectomy followed by ablation of thyroid tissue remnants and possible metastases by means of radioactive iodine. After complete destruction of remnants, metastases or recurrence can be detected by measurement of the serum thyroglobulin level as well as by radionuclide methods. Here we report on the sensitivity of diagnostic I-123 scintigraphy and serum thyroglobulin measurement for tumour detection in patients with proven recurrence or metastases. Fifty-five patients who received their first high activity (1,850-5,550 MBq) of I-123 therapy after total thyroidectomy and I-131 ablation were included in the study. The thyroglobulin level was measured both during TSH-suppressive L-thyroxine therapy (Tg-on) and 4-6 weeks after L-thyroxine withdrawal (Tg-off, TSH>0 mU/l). Prior to treatment, whole-body scanning (WBS) was performed 24 h after the administration of 111-370 MBq I-123. The therapeutic activity of 1,850-5,550 MBq I-131 was administered within 24 h after diagnostic scanning. The mean interval between I-131 therapy and post-therapeutic WBS was 8.6 days (range 3-15 days). The sensitivity of WBS, Tg-on and T-off was 75%, 82% and 98%, respectively. The overall sensitivity of the combination of Tg-on with WBS and of Tg-off with WBS was 95% and 100%, respectively. In 12 out of 51 cases either Tg-off or Tg-on or both T-on and To-off levels were elevated while I-123-WBS was negative. More lesions were visible on the post-therapeutic I-131 scan than on the corresponding diagnostic I-123 scan (n=13). Tg values increased significantly (P<0.0001) after thyroid hormone withdrawal. Early treatment of distant metastases or tumour remnants of differentiated thyroid carcinoma is favoured and I-131 treatment should also be considered in patients with a negative WBS but positive serum Tg level. The finding of a positive Tg-off level, which is clearly above the corresponding Tg-on value, is sufficient to make this decision. Additional diagnostic I-123 WBS will not improve sensitivity.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 50 条
  • [41] Radioiodine whole body scan pitfalls in differentiated thyroid cancer
    Basso, Cristina
    Colapinto, Alessandra
    Vicennati, Valentina
    Gambineri, Alessandra
    Pelusi, Carla
    Di Dalmazi, Guido
    Rizzini, Elisa Lodi
    Tabacchi, Elena
    Golemi, Arber
    Calderoni, Letizia
    Fanti, Stefano
    Pagotto, Uberto
    Repaci, Andrea
    ENDOCRINE, 2024, 85 (02) : 493 - 508
  • [42] DIAGNOSTIC EFFECT OF I-131 WHOLE-BODY SCAN IN AFTERCARE OF DIFFERENTIATED THYROID-CARCINOMA
    HUFNER, M
    STUMPF, HP
    HERMANN, HJ
    KIMMIG, B
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1983, 108 (33) : 1234 - 1238
  • [43] Is the therapeutic dose of I-131 based on I-123 whole body scan adequate in well differentiated thyroid cancer patients?
    Park, Y.
    Na, S.
    Choi, W.
    O, J.
    Kim, S.
    Lee, S.
    Sohn, H.
    Chung, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S355 - S355
  • [44] Impact of aditional radioiodine treatment in well differentiated thyroid carcinoma in patients with negative whole-body scan and high thyroglobulin level
    Rocha, C.
    Vieira, F.
    Costa, G.
    Albuquerque, A.
    Freitas, D.
    Silva, F.
    Ferrer-Antunes, A.
    de Lima, J. Pedroso
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S330 - S330
  • [45] Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma
    Shinohara, Shogo
    Kikuchi, Masahiro
    Suehiro, Atsushi
    Kishimoto, Ippei
    Harada, Hiroyuki
    Hino, Megumu
    Ishihara, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 427 - 432
  • [46] Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan
    Saghari, Mohsen
    Gholamrezanezhad, Ali
    Mirpour, Sahar
    Eftekhari, Mohammad
    Takavar, Abbas
    Fard-Esfahani, Armaghan
    Fallahi, Babak
    Beiki, Davood
    NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (07) : 567 - 572
  • [47] THYROGLOBULIN, I-131 WHOLE-BODY SCANS AND RISK-FACTORS IN THE FOLLOW-UP OF DIFFERENTIATED THYROID-CANCER
    BERDING, G
    HUFNER, M
    GEORGI, P
    NUKLEARMEDIZIN, 1992, 31 (01) : 32 - 37
  • [48] Theranostic Surrogacy of [123I]NaI for Differentiated Thyroid Cancer Radionuclide Therapy
    Kim, Su Bin
    Lee, Min Seob
    Song, In Ho
    Park, Hyun Soo
    Kim, Sang Eun
    MOLECULAR PHARMACEUTICS, 2023, 20 (07) : 3460 - 3470
  • [49] Value of 18F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Levels
    Li, Hongyan
    Chen, Xiaomin
    Zhang, Yajing
    Wang, Kun
    Gao, Zairong
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2869 - 2876
  • [50] Usefulness of SPECT/CT for Equivocal Findings on 131I Whole-Body Scan in a Patient With Differentiated Papillary Thyroid Cancer
    Choi, ByungWook
    Kim, Do-Hoon
    Son, Seung-Hyun
    Zeon, SeokKil
    Ahn, Byeong-Cheol
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (02) : E160 - E162